Humoral immunity depends on both rapid and longterm antibody production against invading pathogens. This is achieved by the generation of spatially distinct extrafollicular plasmablast and follicular germinal center (GC) B cell populations, but the signals that guide responding B cells to these alternative compartments have not been fully elucidated. Here, we show that expression of the orphan G protein-coupled receptor Epstein-Barr virus-induced gene 2 (EBI2, also known as GPR183) by activated B cells was essential for their movement to extrafollicular sites and induction of early plasmablast responses. Conversely, downregulation of EBI2 enabled B cells to access the center of follicles and promoted efficient GC formation. EBI2 therefore provides a previously uncharacterized dimension to B cell migration that is crucial for coordinating rapid versus long-term antibody responses.
INTRODUCTION
Dynamic changes in lymphocyte localization are fundamental to the rapid and efficient production of protective antibodies. Antibody responses are initiated by the relocalization of antigenengaged B cells to the B zone-T zone (B-T) boundary where cognate interactions with T cells drive initial B cell proliferation (Kelsoe and Zheng, 1993; Okada and Cyster, 2006) . Proliferating B cell blasts subsequently proceed down one of two independent pathways of migration and differentiation (Jacob et al., 1991; Liu et al., 1991) . Responding B cells can migrate from the B-T boundary to extrafollicular areas where they are induced to rapidly expand and differentiate into plasmablasts and plasma cells (MacLennan et al., 2003) . These transient antibody-secreting cells provide the most immediate source of antigen-specific antibodies. Alternatively, antigen-engaged B cells can localize in the central, follicular dendritic cell (FDC)-rich region of the follicle to form germinal centers (GCs) (MacLennan, 1994) . B cells proliferating in GCs give rise to high-affinity clones and exit the GC as long-lived plasma cells and memory B cells (Manz et al., 2005; O'Connor et al., 2003) . This second GC-dependent pathway of B cell differentiation provides a sustained source of antibodies with enhanced antigen neutralization potential and mediates long-term immunity against reinfection. The early changes in positioning that recruit responding B cells to either the extrafollicular or the GC pathway of antibody production are therefore crucial for coordinating rapid versus long-term humoral responses.
Lymphocyte mobility and homing is modulated by the chemoattractant receptor subfamily of G protein-coupled receptors (GPCRs) (Campbell et al., 2003; Rot and von Andrian, 2004) . B cell migration and position are controlled to a large extent by the lymphoid chemokines CXCL13, CXCL12, CCL19, and CCL21 and the regulated expression of their receptors CXCR5, CXCR4, and CCR7 (Allen et al., 2004; Forster et al., 1996; Forster et al., 1999; Hargreaves et al., 2001; Nie et al., 2004; Reif et al., 2002) . Homing of B cells to B cell follicles is dependent on their expression of CXCR5 (Forster et al., 1996) , whereas their movement to the B-T boundary after antigen encounter is directed by the rapid upregulation of CCR7 (Reif et al., 2002) . As activated B cells differentiate into plasma cells, they downregulate CXCR5 and CCR7 and upregulate CXCR4, which is critical for their localization in the splenic red pulp and subsequent accumulation in the bone marrow (Hargreaves et al., 2001) . Expression of CXCR5 is retained on B cells seeding GCs and, together with CXCR4, mediates the organization of GCs (Allen et al., 2004) . Although differential expression of these chemokine receptors on plasma cells and GC B cell plays an important role in the localization of these populations to their distinct microenviroments, it is unclear whether additional factors contribute to the migration of activated B cells to extrafollicular sites versus follicular GCs.
In an effort to discover additional GPCRs directing the migratory events of responding B cells, we identified Epstein-Barr virus (EBV)-induced gene 2 (EBI2) as a promising candidate. The gene encoding EBI2 (Ebi2, also known as Gpr183) was originally identified together with Ebi1 (Ccr7) as the most highly upregulated gene in EBV-infected Burkitt's lymphoma cells (Birkenbach et al., 1993) . EBI2 was subsequently reported to be most homologous to members of the lipid and purine GPCR family (Rosenkilde et al., 2006; Surgand et al., 2006) . Although lacking any close homology partner in the chemokine receptor family, EBI2 signals through the pertussis-sensitive Ga i protein, similarly to many chemokine receptors (Rosenkilde et al., 2006) . This orphan GPCR is predominantly expressed in lymphoid tissues and high mRNA expression has been observed in naive B cells (Birkenbach et al., 1993; Rosenkilde et al., 2006) . The already high constitutive expression of Gpr183 present in naive B cells is further increased by B cell receptor (BCR)-triggered NF-kB activation, although this upregulation is only transient (Glynne et al., 2000) . In contrast, GC B cell differentiation is associated with the shut down of Gpr183 expression, which is controlled by the transcriptional repressor Bcl-6 (Shaffer et al., 2000) . Despite this notable pattern of expression linked to B cell differentiation, the biological function of EBI2 remains undefined.
In this study, we demonstrate a critical role for EBI2 in the regulation of a T cell-dependent antibody response. We show that expression of EBI2 by antigen-specific B cells during the early stages of the response was essential for their normal migration to extrafollicular areas of the spleen and differentiation into plasmablasts. On the other hand, downregulation of EBI2 was found to mediate migration of B cells to the central regions of the B cell follicle and enabled the efficient generation of antigen-specific GC B cells. B cells are therefore guided through secondary lymphoid microenvironments by the modulation of EBI2 expression during T cell-dependent B cell responses. This differential migration ultimately directs plasmablast versus GC B cell differentiation and thus provides a mechanism for balancing rapid versus long-term antibody responses.
RESULTS

EBI2 Deficiency Does Not Affect Lymphoid Architecture nor Chemotaxis to Lymphoid Chemokines
To provide insights into the role of EBI2 in B cell responses, we generated EBI2-deficient mice. Mice lacking the entire EBI2 coding region in all cells (Gpr183 À/À mice) were generated on a C57BL/6 genetic background with a standard gene targeting shown). Histological analysis revealed typical partitioning of B and T cells within the splenic white pulp and resolution of follicular and marginal zone B cell populations ( Figure 1A ). The normal splenic architecture of EBI2-deficient mice contrasts with the disorganization of splenic lymphocytes observed in mice lacking either CXCR5 or CCR7 (Forster et al., 1996; Forster et al., 1999) . Thus, not only was EBI2 not required for the gross organization of lymphocytes in the spleen but its expression also did not substantially influence the in vivo chemotactic activities of the primary lymphocyte chemokine receptors. Accordingly, EBI2-deficient B cells exhibited normal cell-surface expression of CXCR5, CXCR4, and CCR7 (data not shown) and normal in vitro migration to their ligands (CXCL13, CXCL12, and CCL21 respectively) ( Figure 1B (Figure 2A ). Transferred EBI2-deficient B cells exhibited a similar pattern of localization within the follicles of recipient lymph nodes ( Figure S2 ). When GCs were present within recipient follicles, transferred EBI2-deficient B cells were also attracted toward the FDC network but did not enter GCs and instead congregated around them ( Figure 2B ). These data demonstrate that differential expression of EBI2 among B cells had a dramatic effect on their migration, with B cells expressing relatively high amounts of EBI2 localizing to the outer follicle and those with low EBI2 expression moving toward the central FDC-rich region. Modulation of EBI2 expression is therefore a potentially powerful mechanism for relocating B cells to different microenvironments within secondary lymphoid tissues.
EBI2 Regulates in B Cell Responses to T Cell-Dependent Antigen
The best characterized example of modulated EBI2 expression is over the course of T cell-dependent B cell responses, during which antigen-engagement results in a transient increase in Gpr183 expression and subsequent GC B cell differentiation is associated with Gpr183 downregulation (Glynne et al., 2000; Shaffer et al., 2000) . to SRBC immunization (Figures 3A and 3B) . In contrast, EBI2 deficiency did not affect the corresponding GC response ( Figure 3A ) nor did it alter in vitro B cell activation in response to a variety of BCRdependent and -independent stimuli (Figure 3C) . Expression of EBI2 was also not required for normal plasma cell differentiation in vitro ( Figure 3D ). EBI2 therefore appears to play a specific and nonredundant role in the in vivo generation of the extrafollicular plasma cells in response to T cell-dependent antigen.
Expression of EBI2 by B Cells Is Required for Generation of Early T Cell-Dependent Antibody Responses
To analyze in more detail the EBI2-mediated regulation of early B cell responses, we bred anti-hen egg lysozyme (HEL) SW HEL immunoglobulin heavy chain gene-targeted mice onto the Gpr183 À/À background (Phan et al., 2003) . Adoptive transfer of EBI2-deficient SW HEL B cells into WT recipients and challenge with a reduced HEL affinity mutant (HEL 23 ) conjugated to SRBCs (Paus et al., 2006) allowed direct assessment of the B cell-intrinsic function of EBI2 in a T cell-dependent antibody response. Analysis of Gpr183 expression in WT SW HEL B cells confirmed the rapid upregulation of Gpr183 after antigen binding and revealed a strong modulation of the expression of this receptor in differentiating SW HEL B cells in vivo, including marked downregulation in GC B cells ( Figure 4A ) as previously described (Shaffer et al., 2000) . Defects were observed in the response of EBI2-deficient SW HEL B cells from as early as 2 days after immunization. At this point a slight delay in the proliferative expansion of EBI2-deficient relative to WT SW HEL B cells was apparent by comparison of their respective CFSE dilution profiles ( Figure 4B ). Partly as a consequence of this, responding EBI2-deficient SW HEL B cells were detected at reduced frequencies in the spleen of recipient animals throughout the first 5 days after immunization ( Figure 4C ).
Phenotypic analysis of responding EBI2-deficient SW HEL B cells confirmed that the specific defect in T cell-dependent plasmablast generation identified previously in Gpr183 À/À mice (Figures 3A and 3B) could be attributed to the absence of EBI2 from responding B cells. On day 4.5 after activation, 50%-60% of WT SW HEL B cells had acquired a phenotype characteristic of plasmablasts, distinguished by downregulation of B220, upregulation of CD138, and the concomitant switch from surface to cytoplasmic immunoglobulin expression ( Figure 4D ). Among EBI2-deficient SW HEL B cells, however, the proportion of cells with this phenotype was typically <20% ( Figure 4D ) with total plasmablast frequencies being reduced to 10%-20% of WT ( Figure 4E ). In contrast, total frequencies of GC B cells ( Figure 4F ) and early memory B cells (data not shown) generated from EBI2-deficient SW HEL donor B cells did not differ from the WT control. As anticipated from the impaired generation of early plasmablasts, the serum anti-HEL IgM and IgG1 concentrations in recipients of EBI2-deficient SW HEL B cells were only 10%-20% of those in recipients of WT SW HEL B cells ( Figure 4G ), particularly during the initial phase of the response prior to the emergence of plasma cells from GCs. Expression of EBI2 by responding B cells was therefore specifically required to ensure efficient generation of T cell-dependent extrafollicular plasmablasts and the associated early antibody response.
EBI2 Regulates B Cell Migration during Early T Cell-Dependent Responses
The results obtained thus far indicated that EBI2 regulates both B cell migration and the generation of the early T cell-dependent plasmablast response. To explore whether these two activities of EBI2 may be linked, we next assessed by histological analysis the movement of EBI2-deficient SW HEL B cells within the spleen during the early stages of their response to HEL 23 -SRBC. Within 1 day of initial challenge, antigen-stimulated WT SW HEL B cells were localized along the B-T boundary (Figure 5 , day 1) as a result of CCR7-induced migration (Reif et al., 2002) . Despite normal upregulation of CCR7 ( Figure 6A cles proximal to bridging and interfollicular regions. This was not evident, however, in the response of EBI2-deficient SW HEL B cells, which remained localized in central follicular areas proximal to the T cell zone ( Figure 5, day 3) . Responding EBI2-deficient SW HEL B cells still persisted in this location 12 hr later, whereas a large fraction of WT SW HEL B cells had by this time migrated into the bridging channels and red pulp ( Figure 5 , day 3.5). The relative absence of extrafollicular EBI2-deficient SW HEL B cells continued until the peak of the WT extrafollicular plasmablast response on day 4.5, with EBI2-deficient B cells instead predominantly moving into GCs ( Figure 5 , day 4.5). The failure of EBI2-deficient B cells to form a robust extrafollicular plasmablast response therefore correlated directly with greatly reduced migration of responding B cells to the bridging channel and red pulp areas in which these responses occur (MacLennan et al., 2003) . Aberrant migration of responding EBI2-deficient B cells was not the result of a defect in regulation of chemokine receptor expression, given that EBI2-deficient SW HEL B cell subpopulations expressed normal amounts of CXCR5 and CXCR4 ( Figure 6B ). As was observed for naive B cells (Figure 2) , responding B cells therefore required EBI2 in order to move away from the central area of the follicle. On the basis of this observation, it is likely that EBI2 controls plasmablast differentiation primarily by facilitating the migration of responding B cells to the extrafollicular microenvironments where this differentiation process is sustained.
Downregulation of EBI2 during B Cell Differentiation Promotes Efficient GC Responses
The migration of EBI2-deficient naive B cells to the FDC-rich areas of the central follicle (Figure 2 ) coupled with the extensive downregulation of Gpr183 expression associated with GC B cell differentiation (Shaffer et al., 2000) ( Figure 4A ) suggested that the impetus for central follicular localization provided by downregu- hi GC phenotype on day 5, the frequency of GC B cells in responses from SW HEL B cells that were unable to downregulate EBI2 was reduced to 25% of empty vector controls ( Figure 7A ). Histological analysis confirmed the smaller size of GCs forming from SW HEL B cells with constitutive EBI2 expression ( Figure 7B ). Instead, these B cells differentiated en masse into extrafollicular plasmablasts ( Figures  7A and 7B ) and thus produced increased early anti-HEL IgM and IgG1 concentrations in the sera of recipient mice ( Figure 7C ). Despite the dramatic shift in B cell differentiation evident from constitutive EBI2 expression, the overall numbers of responding B cells were not affected ( Figure 7D ). It is evident, therefore, that enforced expression of EBI2 drives extrafollicular plasmablast differentiation, whereas its downregulation facilitates GC B cell differentiation.
DISCUSSION
The early control of extrafollicular versus GC localization of responding B cells is controlled to a large extent by the activity of the chemokine receptors CXCR4, CXCR5, and CCR7. However, CXCR4-deficient plasma cells are not impacted in their access to extrafollicular sites, and GC clusters form, albeit with disorganized structure or orientation, in absence of CXCR4-or CXR5-mediated chemotaxis (Allen et al., 2004; Hargreaves et al., 2001 ). Thus, the existing experimental evidence points toward the involvement of an additional signal in the organization of early migratory events in T cell-dependent B cell responses. Our findings demonstrate that EBI2-driven positioning of B cells is a critical component of the mechanism that segregates activated B cells into the extrafollicular versus GC compartments. First, EBI2-dependent migration of responding B cells toward the bridging channels was required for the generation of the early extrafollicular plasmablast response, a process that was greatly enhanced by enforced expression of EBI2. Furthermore, the downregulation of EBI2 expression associated with GC B cell differentiation was sufficient to drive the accumulation of B cells in the deep FDC-rich regions of the follicle where GCs originate and enhanced the formation of GC responses. Although it is clear from the migration pattern of naive EBI2-deficient B cells that other activation-induced changes are typically required for B cells to enter GCs, our data indicate that the downregulation of Gpr183 by Bcl-6 is one of the critical activities of this transcription factor in mediating GC B cell differentiation (Shaffer et al., 2000) .
EBI2 remains an orphan GPCR and the identity and source of its ligand are yet to be described. Molecular studies of EBI2 have suggested that this receptor has constitutive activity, similar to that observed for many herpesvirus-encoded 7TM receptors (Benned-Jensen and Rosenkilde, 2008; Rosenkilde et al., 2006) . It is conceivable that heterodimerization of EBI2 with other chemokine receptors could positively or negatively regulate their activity (Levoye et al., 2006) . Accordingly, EBI2 deficiency would be expected to affect the in vitro chemotactic responses of B cells to chemokines. Such an outcome was not the case as far as tested. Thus, although our results do not exclude a constitutive receptor activity, they indicate that the potential agonist-independent signaling of EBI2 has no detectable impact on the migration of B cells to chemokines. Nevertheless, it remains possible that EBI2 modulates B cell responsiveness to chemokines when bound to its ligand. This orphan GPCR therefore is most likely to regulate B cell localization through a ligand that exhibits a spatially defined pattern of production. The migratory behavior of both naive and activated EBI2-deficient B cells indicated that these B cells failed to be attracted to the periphery of B cell follicles and extrafollicular regions, suggesting the presence of an agonist in these areas. Accumulation of B cells and plasma cells in the marginal-zonebridging channels has been observed as a result of unbalanced chemokine responsiveness (Hargreaves et al., 2001; Reif et al., 2002) . Similarly, autoreactive B cell blasts tend to localize to the red pulp-T zone border (Phan et al., 2003; Seo et al., 2002; William et al., 2002) . The reasons for this homing pattern are unclear and suggest the existence of an unknown factor driving the lodgment of cells to this splenic subcompartment. Although our findings reveal EBI2 as a good candidate for mediating such localization, the extent of its contribution remains to be defined. Nevertheless, EBV-infected B cells, which are induced to express high amounts of EBI2 (Birkenbach et al., 1993) , have been reported to migrate to extrafollicular regions and to avoid GCs during infectious mononucleosis (Niedobitek et al., 1992) , which is in accordance with our results on EBI2 function.
For this study we have used the intermediate affinity mutant antigen HEL 23 for immunization. However, we have observed a similar defect in the plasmablast differentiation of EBI2-deficient SW HEL B cells over a 10,000-fold affinity range by using WT HEL or the low-affinity mutant HEL 33 (data not shown). This indicates that increasing or decreasing BCR signal strength, which is known to regulate the plasmablast response (Benson et al., 2007; Paus et al., 2006) , does not correct or exacerbate the defective response of EBI2-deficient B cells. Consistent with this result, the in vitro activation and proliferation of B cells was not affected by absence of EBI2, and therefore a contribution of EBI2 to the signals required for efficient B cell stimulation is unlikely. Notably, expression of EBI2 was also not required for normal in vitro plasmablast differentiation. It is still possible, however, that signals delivered by EBI2 can directly trigger or regulate gene expression programs that drive plasmablast differentiation. On the other hand, the guidance of responding B cells to distinct microenvironments mediated by modulation of EBI2 expression may subject them to alternative extracellular milieus that could direct their subsequent lineage commitment. Thus, EBI2-deficient B cells may predominantly form GC B cells in vivo because of the fact that they remain in a microenvironment proximal to the FDC network, in which antigen deposits and ( Lam et al., 2008; Shaffer et al., 2000) . In contrast, we have only seen minimal differences in the expression of Gpr183 mRNA in SW HEL B cells stimulated with HEL antigen of different affinities (data not shown). Although regulation of EBI2 is an important component of the early commitment of responding B cells to the extrafollicular versus GC pathway of differentiation, it is clear that this fundamental decision in B cell fate is a complex interplay of many signals in vivo. However, it remains possible that abnormal regulation of EBI2 expression leads to autoimmune and inflammatory diseases in which the balance between plasmablast and GC B cell differentiation is lost.
The importance of EBI2 for B cell function was first suggested by the dramatic upregulation of this receptor in EBV-transformed B cells and further inferred from its regulation in activated and GC B cells (Birkenbach et al., 1993; Glynne et al., 2000; Shaffer et al., 2000) . An involvement of EBI2 in pathology has also been suggested by its dysregulated expression in B cell-associated autoimmune and neoplastic diseases (Aalto et al., 2001; Ye et al., 2003) . However, the function of EBI2 and the significance and implications of its modulation have long awaited clarification. This study provides evidence for a biological function of EBI2 and indicates that this receptor provides an extra dimension to B cell migration and differentiation. Modulation of EBI2 expression is necessary for ensuring both the rapid and long-term antibody production that are required for optimal protection against pathogens. Identification of the putative ligand for EBI2 and elucidation of the molecular mechanisms by which it controls B cell migration and differentiation may prove valuable in designing new vaccine strategies and potential therapeutics for immune disorders. Figure S1 . Analysis of bone marrow, thymus, spleen, lymph nodes, and peritoneal cavity cells did not reveal any defect in the development of the immune system of Gpr183 À/À mice. SW HEL mice and Prdm1 +/gfp reporter mice have been described previously (Kallies et al., 2004; Phan et al., 2003) . C57BL/6 and CD45.1 congenic C57BL/6 (B6.SJL/ ptprc a ) mice were obtained from the Animal Resources Centre (Perth, Australia). All mice were maintained on a C57BL/6 genetic background and housed in a specific pathogen-free environment in the Garvan Institute Biological Testing Facility. All experimental protocols were approved by the Garvan/ St. Vincent's Animal Ethics Committee.
Retroviral Transduction of Hematopoietic Stem Cells
The coding sequence of EBI2 was amplified by PCR from C57BL/6 genomic DNA and inserted into an MSCV2.2-based retroviral vector containing eGFP as an expression marker downstream of the internal ribosomal entry site (IRES). Retrovirus-containing supernatant was generated with the Phoenix-E packaging cell line together with pCL-Eco packaging vector as described (Swift et al., 2001) . Bone marrow cells were extracted from the femur of SW HEL mice and cultured for 24 hr in RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin in the presence of 50 ng/ml mSCF, 20 ng/ml IL-3, and 50 ng/ml IL-6 (all from R&D Systems) before spin-infecting with retroviral supernatants and 4 mg/ml polybrene (Sigma). After infection, cells were cultured for additional 24 hr and then used for reconstituting lethally irradiated C57BL/6 recipient mice. Chimeric mice had frequencies of HEL-binding B cells comparable to SW HEL mice, with 30%-50% of B cells being transduced, as assessed by GFP expression.
Adoptive Transfers and Immunizations
The adoptive transfer system, mutant HEL 23 protein, and its conjugation to SRBCs have been described in detail previously (Brink et al., 2008; Paus et al., 2006 
Flow Cytometry
Splenocytes were prepared, stained for surface molecules, and analyzed on a FACSCanto (BD Biosciences) as previously described (Phan et al., 2005) . Intracellular staining was performed after fixation with 10% formalin and permeabilization with 0.2% polyethylene sorbitan monolaurate. HEL-binding B cells were detected with 200 ng/ml HEL (Sigma-Aldrich) and purified HyHEL9 hybridoma supernatant conjugated to Alexa Fluor 647 (Molecular Probes). The following antibodies and reagents were used for cell staining: anti-CD184/CXCR4-biotin (2B11; BD Biosciences), anti-CXCR5-biotin (2G8; BD Biosciences), anti-CCR7-biotin (4B12; eBiosciences), anti-CD138-biotin (281.2; BD Biosciences), anti-IgG1-biotin (A85-1; BD Biosciences), PNA-biotin (Vector Laboratories), streptavidin-PE (BD Biosciences), anti-CD86-PE (GL1; BD Biosciences), anti-CD45.1-PE/Cy7 (A20; eBiosciences), anti-CD45.2-PerCP/Cy5.5 (104; eBiosciences), anti-GL7-FITC (GL7; BD Biosciences), and anti-CD45R/B220-Pacific blue (RA3-6B2; BD Biosciences).
ELISA
HyHEL10 anti-HEL Ig isotype standards were produced and serum anti-HEL IgM and IgG1 concentrations analyzed by ELISA as previously described (Phan et al., 2003) .
Immunofluorescence Microscopy
Spleen or lymph node sections (5-7 mm) were fixed with acetone and blocked with 30% horse serum. HEL-binding B cells were detected with 100 ng/ml HEL (Sigma) and then detected with polyclonal rabbit anti-HEL serum and sheep anti-rabbit IgG-FITC (Chemicon). T cell areas were revealed with biotinylated anti-CD3 (500A2; eBiosciences) and Alexa Fluor 555-conjugated streptavidin (Invitrogen), B cell follicles were revealed with anti-IgD-Alexa Fluor 647 (11-26c.2a; BioLegend), marginal zone B cells were revealed with anti-IgM-FITC (R6-60.2; BD Biosciences), GC B cells were revealed with anti-GL7-FITC (GL7; BD Biosciences); FDCs were revealed with anti-CD21/35 (7G6; BD Biosciences), and IgG1 + cells were revealed with biotinylated anti-IgG1 (A85.1; BD Biosciencies) and Alexa Fluor 555-conjugated streptavidin (Invitrogen) as indicated. Adoptively transferred naive Gpr183 À/À and WT B cells were distinguished with biotinylated anti-CD45.2 (104; BD Biosciences) and then with HRP-conjugated streptavidin and TSA-direct Cy3-tyramide (PerkinElmer). All images were obtained at 310 objective magnification.
Transwell Migration Assays
Splenocytes from Gpr183 À/À and WT mice were allowed to transmigrate across 5 mm transwell filters (Corning Costar Corp) for 3 hr and were enumerated by flow cytometry as described (Allen et al., 2004) . Chemokines were obtained from R&D Systems. Transwell assays were performed in duplicate for each chemokine concentration and were repeated with cells from a minimum of five different animals of each type. The number of migrated cells was normalized to the migration of control CD45.1 + WT splenocytes added to all wells.
In Vitro Cultures
Cell suspensions from spleens or lymph nodes of Gpr183 À/À and WT mice were prepared in RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 10 mM HEPES, 100 U/ml penicillin, 100 mg/ml streptomycin, and 55 mM 2-ME and stimulated with 10 mg/ml goat anti-mouse IgM (Jackson ImmunoResearch), 5 mg/ml anti-CD40 mAb (HM40-3; BD Biosciences), or 2.5 mg/ml LPS. CD86 upregulation on B cells compared to unstimulated cells was analyzed by flow cytometry 24 hr after stimulation. For analysis of proliferation, B cells purified by magnetic cell sorting were labeled with CFSE prior to culturing (Phan et al., 2003) and cell division was assessed by flow cytometry after 3 days. For analysis of plasma cell differentiation, B cells were purified from from Gpr183 À/À Prdm1 +/gfp and Prdm1 +/gfp reporter mice and cultured for 4 days with 10 mg/ml goat antimouse IgM (Jackson ImmunoResearch) plus 10 ng/ml IL-4 and 2 ng/ml IL-5 (Sigma-Aldrich) or 10 mg/ml LPS. SW HEL splenocytes were stimulated with 500 ng/ml HEL 23 for 1 and 24 hr before analysis of Gpr183 expression.
Statistical Analysis
Levels of statistical significance between means were calculated by unpaired two-tailed Student's t test.
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